CEO exercised or converted 8,832 BSX derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Feb 13, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Feb 18, 2026
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001225208-26-002135
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly IssuerBOSTON SCIENTIFIC CORP Reporting personMichael F Mahoney RelationshipDirector, Officer Officer titleChairman, President & CEO TableNon-derivative (Table I) Transaction dateFeb 13, 2026 Acquired / disposedAcquired (A) Shares owned after1,692,025 Footnotes from the filing
- Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Around the same time
Gilbert Ray Cisneros, Jr. boughtDemocrat, Representative, CA district 31D · CA-314 different filers disclosed BSX within 90 days. Disclosed 27 days after the transaction; reported as an official range, not an exact amount.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
